Background: Depressive disorders are common among those with bipolar affective disorder (BAD) and may necessitate the use of antidepressants. This has been suggested to precipitate manic episodes in some patients.
Objectives: This study aims to determine the prevalence of and factors associated with manic switch in patients with BAD being treated with antidepressants.
Methods: Case notes of patients who were treated at a Nigerian neuropsychiatric hospital for a BAD from 2004 to 2015 were reviewed. BAD diagnosis was made using ICD-10 criteria. Treatment for bipolar depression included monotherapy (i.e. antidepressants, antipsychotics or mood stabilisers) or combination therapy (mood stabiliser with an antidepressant or a combination of mood stabilisers, antipsychotics and antidepressants). The primary outcome measure was a switch to mania or hypomania within 12 weeks of commencing an antidepressant.
Results: Manic or hypomanic switch (MS) was observed in 109 (44.3%) of the participants. Female gender, younger age, number of previous episodes and a past history of psychiatric hospitalisation were all significantly associated with a risk of MS. There was no significant difference in the rate of MS in either those treated with adjunct antidepressants therapy with a mood stabiliser or an antipsychotic or those placed on a combination of antidepressants, antipsychotics and mood-stabilising agents.
Conclusion: A large proportion of patients with BAD on antidepressants experience medication-induced manic or hypomanic switch.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244419 | PMC |
| http://dx.doi.org/10.4102/sajpsychiatry.v24i0.1215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
J Affect Disord
December 2024
Louis A. Faillace Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center at Houston, 1941 East Rd, Houston, TX 77054, USA. Electronic address:
Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic use in individuals with BD.
View Article and Find Full Text PDFEfficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis.
BMJ Ment Health
November 2024
Institute of Health Data Analytics & Statistics, College of Public Health, National Taiwan University, Taipei, Taiwan.
Article Synopsis
- The study researched the optimal dose of lurasidone for treating bipolar depression, focusing on efficacy, acceptability, and metabolic/endocrine effects.
- It reviewed five clinical trials involving 2,032 patients and found that doses between 40-60 mg significantly improved depression, anxiety, and quality of life while experiencing manageable side effects.
- Results indicated that while higher doses led to increased side effects and weight gain, a 40-60 mg dose was generally the best choice for treatment without major risks of dropout or manic switch.
Responses to clinical treatment of bipolar versus unipolar depressive episodes in women versus men.
J Psychopharmacol
November 2024
International Consortium for Mood and Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, MA, USA.
Background: Whether responses to treatment of major depressive episodes differ between women and men or with bipolar (BD) and major depressive disorders (MDD) remains unresolved.
Aims: To test for diagnostic and sex differences in responses to treatment of depression.
Methods: We compared changes in the 21-item Hamilton Depression Rating Scale (HDRS) ratings of depression ( = 3243) between women (64.
Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
J Clin Psychiatry
October 2024
Yale Depression Research Program, Department of Psychiatry at the Yale School of Medicine and the Yale Psychiatric Hospital, New Haven, Connecticut.
Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression treated with ketamine/ esketamine in a real-world setting.
View Article and Find Full Text PDFFull-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data.
J Affect Disord
December 2024
US Medical Affairs, AbbVie, Florham Park, NJ, United States. Electronic address:
Introduction: Patients with bipolar I disorder may experience mood destabilization or treatment-emergent affective switch (TEAS) from one symptom pole to the other spontaneously or following treatment. Optimal treatment should address symptoms from both poles without precipitating destabilization.
Methods: These were pooled post hoc analyses of data from randomized, double-blind, placebo-controlled studies of cariprazine 3-12 mg/d for bipolar I mania (NCT00488618, NCT01058096, NCT01058668) and cariprazine 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!